Praxisrelevante pharmakogenetische Diagnostik zur Verbesserung der Arzneimitteltherapie

Genetische Varianten in Arzneimittel-metabolisierenden Enzymen und Arzneimitteltransportern tragen dazu bei, die Wirkung von Medikamenten zu verbessern oder unerwünschte Arzneimittelwirkungen (UAW) zu vermeiden. Dieser Beitrag fasst den aktuellen Wissensstand zu klinisch relevanten Beispielen zusammen.

Abstract

Pharmacogenomics (PGx) is a key component of personalized medicine to improve clinical outcome of drug therapy and/or to avoid adverse drug reactions. Major efforts are currently spent internationally to implement PGx diagnostics into clinical practice. Evidence-based recommendations for dose-adjusted treatment which are established by international expert groups covering clinical and pharmacological expertise are publicly available. Clinical relevant examples for PGx diagnostics such as genetic testing for dihydropyrimidin-dehydrogenase and thiopurin-S-methyltransferase, as well as for various cytochrome P450 enzymes are summarized to promote the clinical implementation process of PGx in Germany.

Schlüsselwörter

Pharmakogenomik - personalisierte Medizin - Zytochrom P450 - Arzneimittelnebenwirkung - Genvariante

Key words

pharmacogenomics - personalized medicine - cytochrome P450 - adverse drug reaction - genetic variation

Publikationsverlauf

Artikel online veröffentlicht:
04. Januar 2021

• Literatur

• 1 Roden DM, McLeod HL, Relling MV. et al. Pharmacogenomics. Lancet 2019; 394: 521-532
• 2 Chenoweth MJ, Giacomini KM, Pirmohamed M. et al. Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. Clin Pharmacol Ther 2020; 107: 57-61
• 3 Fisel P, Schaeffeler E, Schwab M. DNA Methylation of ADME Genes. Clin Pharmacol Ther 2016; 99: 512-527
• 4 Schärfe CPI, Tremmel R, Schwab M. et al. Genetic variation in human drug-related genes. Genome Med 2017; 9: 117
• 5 U.S. Food and Drug (FDA). Table of Pharmacogenomic Biomarkers in Drug Labeling. Im Internet (Stand: 31.10.2020): https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
• 6 Richtlinie der Gendiagnostik-Kommission (GEKO) für die Beurteilung genetischer Eigenschaften hinsichtlich ihrer Bedeutung für die Wirkung eines Arzneimittels bei einer Behandlung gemäß § 23 Abs. 2 Nr. 1b GenDG. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2017; 60: 472-475
• 7 Tamm R, Mägi R, Tremmel R. et al. Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies. Clin Pharmacol Ther 2017; 101: 684-695
• 8 Schaeffeler E, Fischer C, Brockmeier D. et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14: 407-417
• 9 Schaeffeler E, Jaeger SU, Klumpp V. et al. Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry. Genet Med 2019; 21: 2145-2150
• 10 Relling MV, Schwab M, Whirl-Carrillo M. et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther 2019; 105: 1095-1105
• 11 Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Rote-Hand-Brief zu 5-Fluorouracil- (i. v.), Capecitabin- und Tegafur-haltigen Arzneimitteln: Tests vor Behandlungsbeginn zur Identifizierung von Patienten mit DPD-Mangel. 2020. Im Internet (Stand: 31.10.2020): www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2020/rhb-fluorouracil.html
• 12 Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. Positionspapier zur DPD-Testung veröffentlicht 2020. Im Internet (Stand: 31.10.2020): www.dgho.de/aktuelles/news/news/2020/positionspapier-zur-dpd-testung-veroeffentlicht
• 13 Kassenärztliche Bundesvereinigung KdöR. Test auf DPD-Mangel neue Leistung im EBM 2020. Im Internet (Stand: 31.10.2020): www.kbv.de/html/1150_48070.php
• 14 Amstutz U, Henricks LM, Offer SM. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther 2018; 103: 210-216
• 15 Toffoli G, Innocenti F, Polesel J. et al. The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. Clin Pharmacol Ther 2019; 105: 994-1002
• 16 Clancy JP, Johnson SG, Yee SW. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clin Pharmacol Ther 2014; 95: 592-597
• 17 Savant AP, McColley SA. Cystic fibrosis year in review 2018, part 2. Pediatr Pulmonol 2019; 54: 1129-1140
• 18 Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-141
• 19 Desta Z, Gammal RS, Gong L. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clin Pharmacol Ther 2019; 106: 726-733
• 20 Claassens DMF, Vos GJA, Bergmeijer TO. et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. N Engl J Med 2019; 381: 1621-1631
• 21 Scott SA, Sangkuhl K, Stein CM. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013; 94: 317-323
• 22 Moriyama B, Obeng AO, Barbarino J. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther 2017; 102: 45-51
• 23 Patel JN, Hamadeh IS, Robinson M. et al. Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant. Clin Pharmacol Ther 2020; 107: 571-579
• 24 Dutch Pharmacogenetic Working Group of the KNMP. CYP2D6: tramadol. Im Internet (Stand: 31.10.2020): www.g-standaard.nl/risicoanalyse/B0001589.PDF
• 25 Crews KR, Gaedigk A, Dunnenberger HM. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 2014; 95: 376-382
• 26 U.S. Food and Drug (FDA). FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. Im Internet (Stand: 31.10.2020): www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-restricts-use-prescription-codeine-pain-and-cough-medicines-and
• 27 Brauch H, Schroth W, Goetz MP. et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 2013; 31: 176-180
• 28 Goetz MP, Sangkuhl K, Guchelaar HJ. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther 2018; 103: 770-777
• 29 Birdwell KA, Decker B, Barbarino JM. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther 2015; 98: 19-24
• 30 Dutch Pharmacogenetic Working Group of the KNMP. CYP2D6: tramadol. Im Internet (Stand: 31.10.2020): https://www.g-standaard.nl/risicoanalyse/B0001694.PDF
• 31 Ramsey LB, Johnson SG, Caudle KE. et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014; 96: 423-428
• 32 Krebs K, Milani L. Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. Hum Genomics 2019; 13: 39